Abstract
The role of A1 and A3 receptors is discussed based on data almost exclusively obtained in the hippocampus. This brain area, where A1 receptor expression predominates, has been a matter of intensive research in the adenosine field. Interestingly, in the last decade, the relevance of the much less expressed adenosine receptor in the hippocampus, the A2A receptor, has been put forward. These two high affinity receptors operate as effective regulators of a number of neurotransmitters and/or neuromodulators, through modulation of their release, action, or even inactivation. Therefore, A1 and A2A receptors constitute a must in the discussion about adenosine receptors in the hippocampus, and consequently, about the potential implications of their pharmacological manipulation and drug targeting.
Keywords: Adenosine receptors, brain-derived neurotrophic factor, cannabinoids, γ-aminobutyric acid, glutamate, hippocampus, neuroprotection, vasoactive intestinal peptide, Adenosine receptors, brain-derived neurotrophic factor, cannabinoids, aminobutyric acid, glutamate, hippocampus, neuroprotection, vasoactive intestinal peptide, ACh, AMPA
CNS & Neurological Disorders - Drug Targets
Title:From A1 to A3 en passant Through A2A Receptors in the Hippocampus: Pharmacological Implications
Volume: 11 Issue: 6
Author(s): Ana M. Sebastiao, Filipa F. Ribeiro and Joaquim A. Ribeiro
Affiliation:
Keywords: Adenosine receptors, brain-derived neurotrophic factor, cannabinoids, γ-aminobutyric acid, glutamate, hippocampus, neuroprotection, vasoactive intestinal peptide, Adenosine receptors, brain-derived neurotrophic factor, cannabinoids, aminobutyric acid, glutamate, hippocampus, neuroprotection, vasoactive intestinal peptide, ACh, AMPA
Abstract: The role of A1 and A3 receptors is discussed based on data almost exclusively obtained in the hippocampus. This brain area, where A1 receptor expression predominates, has been a matter of intensive research in the adenosine field. Interestingly, in the last decade, the relevance of the much less expressed adenosine receptor in the hippocampus, the A2A receptor, has been put forward. These two high affinity receptors operate as effective regulators of a number of neurotransmitters and/or neuromodulators, through modulation of their release, action, or even inactivation. Therefore, A1 and A2A receptors constitute a must in the discussion about adenosine receptors in the hippocampus, and consequently, about the potential implications of their pharmacological manipulation and drug targeting.
Export Options
About this article
Cite this article as:
M. Sebastiao Ana, F. Ribeiro Filipa and A. Ribeiro Joaquim, From A1 to A3 en passant Through A2A Receptors in the Hippocampus: Pharmacological Implications, CNS & Neurological Disorders - Drug Targets 2012; 11 (6) . https://dx.doi.org/10.2174/187152712803581074
DOI https://dx.doi.org/10.2174/187152712803581074 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structure, Roles and Inhibitors of a Mitotic Protein Kinase Haspin
Current Medicinal Chemistry Pharmacokinetics of Topical Ocular Drug Delivery: Potential Uses for the Treatment of Diseases of the Posterior Segment and Beyond
Current Drug Metabolism Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Venom Peptide Modulators of the Immune System
Inflammation & Allergy - Drug Targets (Discontinued) Cholesterol and Apoe: A Target for Alzheimers Disease Therapeutics
Current Drug Targets - CNS & Neurological Disorders Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Therapeutic Monitoring of Carbamazepine in Epilepsy Patients by Highly Sensitive LC/MS Method and its Clinical Applications
Current Analytical Chemistry Engineering of Conotoxins for the Treatment of Pain
Current Pharmaceutical Design Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume I)
CNS & Neurological Disorders - Drug Targets Preliminary Evaluation of Anticonvulsant Activity of Some Aminoalkanol and Amino Acid Cinnamic Acid Derivatives
Letters in Drug Design & Discovery Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?
Current Molecular Pharmacology Alzheimer’s Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function
Current Alzheimer Research Adult Neurogenesis in Epileptogenesis: An Update for Preclinical Finding and Potential Clinical Translation
Current Neuropharmacology Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications
Current Neuropharmacology The Canonical Wnt Signaling Pathway in Autism
CNS & Neurological Disorders - Drug Targets Nongenomic Thyroxine Regulation of Voltage-gated Sodium Current During Embryonic Development
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial [Hot Topic:Ion Channels as a Target for Drug Design (Executive Editor: Kwok-Keung Tai)]
Current Pharmaceutical Design AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Gold - Old Drug with New Potentials
Current Medicinal Chemistry